Cembra Money Bank (CMBN) H1 2024 earnings summary
Event summary combining transcript, slides, and related documents.
H1 2024 earnings summary
3 Feb, 2026Executive summary
Net income rose 4% to CHF 78.3 million in H1 2024, with revenues up 6% to CHF 268.0 million, driven by repricing, fee income, and selective growth across lending and payments.
The segment-based organization in Lending (Personal loans + Auto) and Payments (Cards + BNPL) is operational and delivering growth.
Major transformation milestones included a full-scale roll-out of the new auto banking platform and a revamped digital savings offering.
Cost/income ratio improved to 50.4% (H1 2023: 53.2%), with further reductions targeted.
The company confirms its midterm targets and dividend outlook.
Financial highlights
Net income increased 4% to CHF 78.3 million and net revenues rose 6% to CHF 268.0 million year-over-year.
Net interest income up 8% to CHF 183.6 million; commission and fee income up 2% to CHF 84.4 million.
Net financing receivables rose 2% to CHF 6.8 billion, with growth across all products.
Loss rate normalized to 1%, up from 0.7% in H1 2023, in line with guidance.
ROE reached 12.7%, and tier one capital stood at 17.1%.
Outlook and guidance
Net interest margin expected to rebound to 5.5% by 2025–2026; cost/income ratio targeted below 49% for 2024 and below 39% by 2026.
Full-year loss rate expected around 1%; ROE for the full year anticipated between 13%–14%.
Dividend policy of at least CHF 4 per share confirmed, with increases in line with sustainable earnings growth.
Mid-term targets include financing receivables growth of 1–3% p.a. and increasing dividend.
Tier 1 capital ratio target remains above 17%.
Latest events from Cembra Money Bank
- Net income up 5% to CHF 179.6–180m, with improved efficiency and 2026 ROE targeted at 15%.CMBN
H2 202519 Feb 2026 - Net income up 8% to CHF 170.4m, with improved efficiency and a higher dividend.CMBN
H2 202417 Dec 2025 - Net income up 11% to CHF 87.2m, cost efficiency improved, and 2025 outlook reaffirmed.CMBN
H1 202524 Jul 2025